EVAPORATE 9-Month Results Show Icosapent Ethyl Did Not Significantly Slow Low-Attenuation Plaque Progression vs. Placebo in Atherosclerosis Patients on Statins
An interim analysis showed that icosapent ethyl did not significantly slow progression of low-attenuation plaque in comparison with placebo in patients with coronary atherosclerosis who were already receiving statins, according to results presented Monday at the American Heart Association Scientific Sessions in Philadelphia.